President Spetzler sells $14.8m in Caris Life Sciences stock

Caris Life Sciences President David Baxley Spetzler disposed of a significant portion of the company's stock on September 3 and 4, 2026. He sold $14,834,106 worth of common shares, while simultaneously purchasing $3,050,000 worth of shares through option exercises on the same days. The insider transactions occurred as Caris Life Sciences' stock price hovered around $25.07, giving the company a market capitalization of $7.16 billion.

The stock was deemed overvalued by InvestingPro, although it had generated strong returns with a 26% gain over the past six months. Mr. Spetzler exercised options to acquire 1,000,000 shares at $2.44 per share on September 3, and subsequently sold 393,100 shares at prices ranging from $24.32 to $25.31. On September 4, he exercised options for an additional 250,000 shares at $2.44 per share and sold 119,212 shares at a weighted average price of $24.76.

These sales were executed to cover the exercise price of the vested stock options and tax withholding obligations. The insider retained all remaining shares acquired through exercise. As a result, Mr. Spetzler now owns 1,182,871 shares of Caris Life Sciences common stock. Caris Life Sciences reported robust financial results for Q2 2026, exceeding revenue expectations and raising its full-year guidance.

The company's molecular profiling services contributed to a 45% revenue growth from the previous year.